United States Refurbished DNA Sequencing Platforms Market to Hit $140 Million by 2031 at 4.5% CAGR, Leveraging Every Ounce of Cost-Effective Genomics Innovation | DataM Intelligence

Leander, Texas and TOKYO, Japan - Nov. 18, 2025. According to DataM Intelligence, the United States Refurbished DNA Sequencing Platforms Market is projected to grow from USD 94 million in 2023 to USD 140 million by 2031, registering a solid CAGR of 4.5% during the forecast period of 2024-2031. Rising budget constraints in academic and clinical labs, explosive growth in precision medicine and large-scale population genomics (e.g., NIH All of Us, Cancer Moonshot), and continuous improvements in recertification protocols are driving demand for high-performance, factory-refurbished sequencing systems. These platforms deliver near-new accuracy and throughput while cutting capital costs by up to 60% compared to brand-new units. Leading systems such as certified pre-owned Illumina NovaSeq, HiSeq, NextSeq, and Thermo Fisher Ion GeneStudio/Genexus dominate the refurbished space, enabling labs to scale oncology, rare disease, and multi-omics research without sacrificing data quality or regulatory compliance.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/refurbished-dna-sequencing-platforms-market?Nitin

Explore the comprehensive Table of Contents for the Refurbished DNA Sequencing Platforms Market, featuring:
✅61 Tables
✅55 Figures
✅197 Pages of detailed insights and forecasts

Competitive Landscape

The market is highly competitive among global genomics leaders, equipment refurbishers, and biotech service providers.

1️⃣Illumina Inc. expanded its certified refurbished program in San Diego, set to ramp up in Q2 2026, increasing access for U.S. academic labs with 25% faster turnaround on NovaSeq units.

2️⃣Thermo Fisher Scientific acquired a leading U.S. refurbishment specialist in Massachusetts, bolstering its domestic supply chain and posting a 18% revenue boost in budget-conscious clinical segments.

3️⃣QIAGEN partnered with four U.S. research consortia to certify refurbished QIAseq platforms for metagenomics, gaining 30% adoption in environmental studies and full HIPAA compliance.

4️⃣Agilent Technologies introduced upgraded refurbished SureSelect systems with AI-optimised workflows, clinching deals with major oncology centres and spurring 20% growth in American sales.

5️⃣Pacific Biosciences (PacBio) launched eco-refurbished Revio sequencers for long-read applications, cutting deployment times by 35% and collaborating with U.S. pharma giants for drug discovery personalisation.

Recent Developments

1. Illumina Inc. demonstrated refurbished AVITI sequencing for rare variant detection at ASHG 2024 in Baltimore (November 2024).

2. Thermo Fisher Scientific established a dedicated refurbishment hub in Carlsbad, California, for nationwide genomics operations (September 2024).

3. QIAGEN enhanced its U.S. platforms with cloud-integrated software for biomarker workflows (June 2025).

4. Agilent Technologies debuted certified refurbished InfinityLab systems for epigenomics research (April 2025).

5. PacBio collaborated on long-read refurbished kits for agricultural genomics, reducing sequencing costs by 45% (February 2025).

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/refurbished-dna-sequencing-platforms-market?Nitin

Growth Drivers

✦ The global genomics research market exceeded USD 25 billion in 2024, with refurbished platforms accounting for 8% of equipment spends, emphasizing the shift to economical sequencing amid escalating R&D budgets.

✦ Precision medicine investments surpassed USD 100 billion worldwide in 2024, driving over 500,000 refurbished sequencing runs annually and accelerating adoption for personalized diagnostics.

✦ Regulatory incentives fueled USD 300 billion in biotech funding by 2025, favoring certified refurbished tools that meet FDA guidelines for clinical-grade data integrity.

✦ U.S. oncology sequencing volumes rose 22% in recent years, incorporating more than 200,000 refurbished platform analyses yearly as cancer screening expands through initiatives like the Cancer Moonshot.

✦ Hardware optimization advancements lowered operational costs by 40%, anticipating USD 150 million in annual efficiencies for U.S. labs by 2030 via refurbished integrations.

Market Segmentation Analysis

By Platform Type: The refurbished DNA sequencing platforms market is segmented into Next-Generation Sequencing, Sanger Sequencing, and Others, with Next-Generation Sequencing leading at 70% share (USD 175 million in 2023), projected to USD 245 million by 2031 at 4.6% CAGR for high-throughput genomics. Sanger Sequencing holds USD 50 million, growing to USD 70 million at 4.4% CAGR via targeted validation applications. Others at 10% (USD 25 million) will reach USD 35 million, while at 4.5% CAGR.

By Application: Oncology Study dominates with 40% share (USD 100 million in 2023), expected to reach USD 140 million by 2031 for tumor profiling demands. Personalized Medicine at 25% (USD 62.5 million) projects to USD 87.5 million, supporting tailored therapies. Biomarker Discovery (15%, USD 37.5 million) advances drug development; Forensics and Others (20%, USD 50 million) scales for investigative and agricultural uses.

By End-User: Research Laboratories leads at 45% (USD 112.5 million in 2023), growing to USD 157.5 million by 2031 via academic grants. Biotechnology and Pharmaceutical Companies at 30% (USD 75 million) reaches USD 105 million for pipeline acceleration. Academic Institutes (15%, USD 37.5 million) enhance training programs; Hospitals and Others (10%, USD 25 million) integrate for clinical diagnostics.

🌍Regional Insights

United States: The U.S. market was valued at USD 0.10 billion in 2023, projected to USD 0.14 billion by 2031 at a 4.5% CAGR, driven by precision oncology growth and NIH funding under the Advanced Research Projects Agency for Health guidelines. Over 70% of labs have adopted refurbished platforms since 2023 for cost savings in 5,000+ facilities.

Canada: Canada's market, at USD 0.025 billion in 2023, grows to USD 0.035 billion by 2031 at a 4.5% CAGR, supported by Genome Canada's CAD 1 billion for genomics infrastructure. Thermo Fisher pilots long-read refurbished systems; industry forecasts 35% adoption rise and 25% cost reductions by 2027 via certified programs.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=refurbished-dna-sequencing-platforms-market?Nitin

Market Outlook and Opportunities: The Global Refurbished DNA sequencing platforms market is at a tipping point, driven by budget constraints in genomics and every ounce of technological evolution in accessible data generation. Valued at USD 0.25 billion in 2023, it is projected to reach USD 0.35 billion by 2031 at a steady 4.5% CAGR. North America, holding over 40% of the global share, leads growth fueled by robust R&D investments, while Asia Pacific benefits from emerging biotech hubs. Advances in certified refurbishment and AI-enhanced analysis support U.S. innovation goals, though challenges like quality assurance variances, supply chain disruptions, and regulatory hurdles persist. Post-pandemic focus on variant surveillance and rising demand for scalable sequencing open significant opportunities for democratized genomics in oncology, personalised care, and research efficiency.

Related Reports:
DNA Sequencing Market - https://www.datamintelligence.com/research-report/dna-sequencing-market?Nitin

Refurbished Medical Devices Market - https://www.datamintelligence.com/research-report/refurbished-medical-devices-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm headquartered in Hyderabad, Telangana, India, dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analyses, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.